上月稔幸

コウヅキトシユキ | Kozuki Toshiyuki

所属機関・部署：
職名：臨床研究センター長
論文 (203件)：

Masahiro Tsuboi, Haruyasu Murakami, Hideyuki Harada, Tomotaka Sobue, Tomohiro Kato, Shinji Atagi, Takaaki Tokito, Tadashi Mio, Hirofumi Adachi, Toshiyuki Kozuki, et al. Treatment patterns and clinical outcomes of resectable clinical stage III non-small cell lung cancer in a Japanese real-world setting: Surgery cohort analysis of the SOLUTION study. Thoracic cancer. 2024. 15. 20. 1541-1552
Takeshi Masuda, Taizo Hirata, Tomohiro Sakamoto, Yukari Tsubata, Eiki Ichihara, Toshiyuki Kozuki, Hiroyasu Shoda, Masanori Motonaga, Takako Yoshida, Miki Fukutani, et al. Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer. Journal of thoracic disease. 2024. 16. 5. 3381-3388
Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, et al. Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial. Lung Cancer. 2024. 191. 107557-107557
Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Takako Inoue, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, et al. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer science. 2024
Makoto Nishio, Shuji Murakami, Hisato Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, et al. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications. 2024. 4. 1. 226-235

MISC (57件)：

Yuka Kato, Taku Noumi, Kazuhiko Saeki, Kiichiro Ninomiya, Toshio Kubo, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Masahiro Tabata, et al. Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group. JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 15
高田一郎, 小田尚廣, 磯崎英子, 原田大二郎, 上月稔幸, 別所昭宏, 細川忍, 横山俊秀, 吉岡弘鎮, 瀧川奈義夫, et al. ALK融合遺伝子陽性非小細胞肺癌患者におけるアレクチニブ耐性後のクリゾチニブの有効性を検討する第II相試験. 日本呼吸器学会誌. 2021. 10. 増刊. 227-227
Kiichiro Ninomiya, Yusuke Okuma, Noriyuki Ebi, Keiju Aokage, Yuko Oya, Tomohiro Sakamoto, Toshiyuki Kozuki, Kaname Nosaki, Katsuyuki Shirai, Tetsuo Nonaka, et al. Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer. Japanese Journal of Lung Cancer. 2021. 91. 2. 95-99
二宮貴一朗, 大熊裕介, 海老規之, 青景圭樹, 大矢由子, 阪本智宏, 上月稔幸, 野崎要, 白井克幸, 野中哲生, et al. 非小細胞肺癌におけるOligometastatic diseaseの管理と治療. 肺癌(Web). 2021. 61. 2
上月稔幸, 津端由佳里, 石川暢久, 藤高一慶, 石井知也, 山崎正弘, 瀧川奈義夫, 藤本伸一, 小谷昌広, 藤原慶一, et al. ドライバー変異陰性非小細胞肺癌に対する免疫チェックポイント阻害剤の実態調査. 肺癌. 2020. 60. 6. 582-582

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る

上月 稔幸

上月稔幸